10-K/A: Translational Development Acquisition Corp. 10-K/A Amendment Filing

Translational Development Acquisition Corp. files an amendment to its 2025 annual report, revising its conclusion on disclosure controls and procedures to 'not effective'.

Summary

• This filing is an amendment (Amendment No. 2) to Translational Development Acquisition Corp.'s Annual Report on Form 10-K for the fiscal year ended December 31, 2025.
• The amendment specifically revises Part II, Item 9A, 'Controls and Procedures', to state that the company's disclosure controls and procedures were not effective as of December 31, 2025.
• New certifications from the Principal Executive Officer and Principal Financial Officer, required by Sarbanes-Oxley Act Sections 302 and 906, are included as Exhibits 31.1, 31.2, 32.1, and 32.2.
• The company's management evaluated the effectiveness of its disclosure controls and procedures as of December 31, 2025, and concluded they were not effective.
• Management also assessed the effectiveness of internal control over financial reporting as of December 31, 2025, using COSO criteria, and determined that internal control over financial reporting was effective.
• There were no changes in internal control over financial reporting during the most recent fiscal quarter that materially affected or are likely to materially affect them.
• The filing does not amend or update any other disclosures from the original filing or Amendment No. 1, except as described.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as having a neutral to slightly negative sentiment due to the explicit statement that disclosure controls and procedures were not effective, although the effective internal financial controls provide some mitigation.

Positives

• Management concluded that the company maintained effective internal control over financial reporting as of December 31, 2025, based on COSO criteria.
• There were no changes in internal control over financial reporting during the most recent fiscal quarter that materially affected, or are reasonably likely to materially affect, the company's internal control over financial reporting.

Negatives

• The company's disclosure controls and procedures were not effective as of December 31, 2025.
• Management acknowledges that disclosure controls and procedures, no matter how well designed, can only provide reasonable, not absolute, assurance, and may not detect all errors or instances of fraud.

Risks

• Inherent limitations in all disclosure controls and procedures mean that no evaluation can provide absolute assurance that all control deficiencies and instances of fraud have been detected.
• The design of disclosure controls and procedures is based on assumptions about future events, and there is no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the assessment of controls and procedures.

Management Comments

• Management evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation.
• Management assessed the effectiveness of our internal control over financial reporting as of December 31, 2025. In making these assessments, Management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control - Integrated Framework (2013).
• Based on our assessments and those criteria, Management determined that we maintained effective internal control over financial reporting as of December 31, 2025.

Industry Context

StockSavvy.ai notes that amendments to SEC filings, particularly those addressing control deficiencies, are common for companies, especially emerging growth companies, as they refine their reporting processes. The focus on disclosure and internal controls is a critical aspect of corporate governance and investor confidence.

Corporate Governance

Stakeholder Impact

• Shareholders: May have concerns regarding the effectiveness of disclosure controls, potentially impacting confidence in the company's reporting accuracy, despite effective internal financial controls.
• Auditors: Will need to consider the disclosed deficiencies in disclosure controls during their audit procedures.
• Management: Must continue efforts to improve disclosure controls and procedures to meet SEC requirements and ensure accurate and timely reporting.

Next Steps

• The company will continue to operate under its established internal control over financial reporting.
• The company will continue to file required reports with the SEC.

Key Dates

Keywords

10-K/A, Amendment, Disclosure Controls, Internal Controls, Sarbanes-Oxley Act, SEC Filing, Financial Reporting, Translational Development Acquisition Corp., Emerging Growth Company, Certifications